VICO
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Vicore Pharma Holding
P/B
Median 2019-2025
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Share price (SEK) | 14.30 | 30.65 | 13.54 | 17.42 | 13.80 | 8.45 | 11.30 |
| Shares | 44.3 | 62.1 | 73.8 | 84.1 | 114.8 | 234.6 | 281.5 |
| Market cap | 633.5 | 1,903.2 | 998.9 | 1,465.1 | 1,584.2 | 1,982.2 | 3,181.2 |
| Enterprise value | 446.1 | 1,584.6 | 627.7 | 1,203.3 | 1,101.5 | 826.2 | - |
| EV/S | - | - | - | - | - | 7.6 | - |
| EV/EBITDA | neg. | neg. | neg. | neg. | neg. | neg. | - |
| EV/EBIT | neg. | neg. | neg. | neg. | neg. | neg. | - |
| P/E | neg. | neg. | neg. | neg. | neg. | neg. | neg. |
| P/B | 1.97 | 5.37 | 2.61 | 5.07 | 3.48 | 1.76 | 2.90 |
| P/S | - | - | - | - | - | 18.1 | 833.4 |
| Dividend yield | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |
| Equity ratio | 94.3 % | 87.2 % | 85.0 % | 85.4 % | 91.8 % | 93.9 % | 89.8 % |
| Gearing ratio | 0.1 % | 0.0 % | 0.1 % | 0.0 % | 0.0 % | 0.0 % | 0.0 % |